Contact Us
Drug Search Results
More Filters [+]

Repaglinide

Alternative Names: repaglinide, gluconorm, r0179, prandin, prandimet
Latest Update: 2025-01-24
Latest Update Note: Clinical Trial Update

Product Description

Repaglinide is a medication used in the management and treatment of diabetes mellitus Type 2. It is in the antihyperglycemic class of drugs. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK559305/)

Mechanisms of Action: Potassium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Repaglinide

Countries in Clinic: Belgium, China, Germany, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Adenocarcinoma|Arthritis, Rheumatoid|Esophageal Cancer|Fallopian Tube Cancer|Gastrointestinal Cancer|Gout|Healthy Volunteers|Malaria|Ovarian Cancer|Overweight|Peritoneal Cancer|Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
HDM1002-106

P1

Not yet recruiting

Overweight

2025-02-01

J5C-MC-FOAF, DC-853104

P1

Completed

Healthy Volunteers

2024-12-31

U1111-1301-9035

P1

Completed

Healthy Volunteers

2024-10-16

U1111-1303-9187

P1

Completed

Healthy Volunteers

2024-08-20

Recent News Events

Date

Type

Title

01/24/2024

News Article

 Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU

09/02/2023

News Article

 The report on the Gemcitabine HCl market size forecasts a 5.1% CAGR growth rate until 2030, providing a detailed and in-depth examination of the market.

09/02/2023

News Article

 Repaglinide market analysis study offers a both qualitative and quantitative analysis of the market and the factors aiding or obstructing its growth with an impressive 7.6% CAGR from 2023-2030

09/02/2023

News Article

 The Levosulpiride market report's foreign opportunities and dynamics analysis delves into the market's size, which is projected to grow at a CAGR of 8.5% from 2023 to 2030, and provides an overview of revenue generation, COVID-19 impact, and application.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions